{"id":"W4391302332","doi":"10.1200/jco.2024.42.4_suppl.581","title":"Avelumab first-line maintenance (1LM) for advanced urothelial carcinoma (aUC): Long-term patient-reported outcomes (PROs) in the phase 3 JAVELIN Bladder 100 trial.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Javelin; Urothelial carcinoma; Avelumab; Metastatic Urothelial Carcinoma; Oncology; Internal medicine; Urology; Carcinoma; Bladder cancer; Cancer; Pembrolizumab; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002217021,0.0004098768,0.000695364,0.0001934259,0.0001841598,0.0006956298,0.0003760507,0.0005900408,0.001994561],"category_scores_gemma":[0.001383654,0.0001846227,0.001112491,0.000299875,0.0003024686,0.0005104914,0.0003301216,0.001619957,0.0002620918],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003855913,"about_ca_system_score_gemma":0.0004727424,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003833307,"about_ca_topic_score_gemma":0.001359436,"domain_scores_codex":[0.9994412,0.0003921263,0.00002373742,0.00004990173,0.00004254845,0.0000504824],"domain_scores_gemma":[0.9992996,0.0001894049,0.0002479416,0.00004153835,0.00003369441,0.0001877493],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.8312887,0.008210069,0.02523544,0.00184586,0.003397808,0.0001212828,0.000168236,0.002270422,0.008141495,0.0003146738,0.004830441,0.1141756],"study_design_scores_gemma":[0.5133399,0.337055,0.1248871,0.0004985339,0.005149997,0.0006344338,0.000155406,0.004154169,0.003620432,0.0006917773,0.009741527,0.00007171417],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9879013,0.007572085,0.0003183648,0.0004299089,0.00009069053,0.0006059997,0.00139048,0.00004347505,0.001647733],"genre_scores_gemma":[0.9927492,0.002278099,0.0006214902,0.0004506655,0.00008432119,0.000931068,0.001806049,0.000009666131,0.001069491],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002217021,"threshold_uncertainty_score":0.01172489,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1351827073390061,"score_gpt":0.4847503011248669,"score_spread":0.3495675937858608,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}